Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A series of SynLeptin peptides, particularly, SynLeptin-2 shows remarkable anti-obesity activities which were verified in animal experiments using mice and rabbits. More
MRI contast medium More
MRI contast medium More
Collagen-based biodegradable matrices for localized drug delivery More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jan 2011 - 124 pages - $1,740
Jul 2011 - 147 pages - $3,835
Jan 2011 - 231 pages - $3,835
Nov 2010 - 260 pages - $600
May 2011 - 25 pages - $250
Feb 2012 - 672 pages - $1,040
Jun 2009 - 118 pages - $1,040
Nov 2009 - 830 pages - $1,040
Jun 2009 - 110 pages - $1,040
Jul 2010 - 98 pages - $750
Your selection
Browse By
- Industry sector
- Ampoule
- Cartridge
- Implant
- Injection vial
- Intramuscular
- Intravenous
- Needle-less
- Pen
- Pre-filled syringe
- Safety needle
- Subcutaneous
- Sustained release
- Unit dose
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us